Advertisement

Topics

Irritable Bowel Syndrome - Pipeline Review, H1 2015

02:29 EDT 22 Jul 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Irritable Bowel Syndrome - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-16. This 123-page report is available in PDF from $2000.

Irritable Bowel Syndrome - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Irritable Bowel Syndrome - Pipeline Review, H1 2015’, provides an overview of the Irritable Bowel Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Irritable Bowel Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Irritable Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Irritable Bowel Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Irritable Bowel Syndrome Overview 10
Therapeutics Development 11
Pipeline Products for Irritable Bowel Syndrome - Overview 11
Pipeline Products for Irritable Bowel Syndrome - Comparative Analysis 12
Irritable Bowel Syndrome - Therapeutics under Development by Companies 13
Irritable Bowel Syndrome - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Irritable Bowel Syndrome - Products under Development by Companies 19
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 21
A. Menarini Industrie Farmaceutiche Riunite Srl 21
Actavis Plc 22
Alba Therapeutics Corporation 23
Alfa Wassermann S.p.A 24
Ardelyx, Inc. 25
Astellas Pharma Inc. 26
Dong-A Socio Group 27
GIcare Pharma Inc 28
Hanmi Pharmaceuticals, Co. Ltd. 29
ImmusanT, Inc. 30
Ironwood Pharmaceuticals, Inc. 31
Juno Therapeutics Inc. 32
Ono Pharmaceutical Co., Ltd. 33
Protagonist Therapeutics Inc. 34
RaQualia Pharma Inc. 35
SK Biopharmaceuticals Co., Ltd. 36
SK Chemicals Co., Ltd. 37
Sumitomo Dainippon Pharma Co., Ltd. 38
Synergy Pharmaceuticals, Inc. 39
Synthetic Biologics, Inc. 40
Takeda Pharmaceutical Company Limited 41
Yuhan Corporation 42
Irritable Bowel Syndrome - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
(Bacillus subtilis + mosapride + Streptococcus faecium) - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ASP-1017 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ASP-7147 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Blautix - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DA-6886 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
DSP-6952 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
eluxadoline - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GIC-1001 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ibodutant - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
larazotide acetate - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
linaclotide - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Monoclonal Antibody…

For more information open Irritable Bowel Syndrome - Pipeline Review, H1 2015.

SKU: GMDHC6702IDB

Original Article: Irritable Bowel Syndrome - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Irritable Bowel Syndrome - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Irritable Bowel Syndrome IBS
Irritable bowel syndrome (IBS) is a common but poorly understood chronic (long-term) condition where the normal functions of the bowel are disrupted. Symptoms of IBS include abdominal pain or discomfort, changes in bowel habits and bloated feelings. ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...